{"url_path":"/sec/bctx/8-k/2026-06-03/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-03","source_url":"https://www.sec.gov/Archives/edgar/data/1610820/0001493152-26-026953-index.html","accession_number":"0001493152-26-026953","cik":"0001610820","ticker":"BCTX","issuer_name":"BriaCell Therapeutics Corp.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1610820/0001493152-26-026953-index.html","primary_entity_key":"0001610820","primary_entity_name":"BriaCell Therapeutics Corp."},"word_count":334,"has_tables":true,"body_markdown":"false\n0001610820\n\n0001610820\n\n2026-05-31\n2026-05-31\n\n0001610820\n\nBCTX:CommonSharesNoParValueMember\n\n2026-05-31\n2026-05-31\n\n0001610820\n\nBCTX:WarrantsToPurchaseCommonSharesNoParValueMember\n\n2026-05-31\n2026-05-31\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n \n\n**UNITED\nSTATES**\n\n**SECURITIES\nAND EXCHANGE COMMISSION**\n\n**WASHINGTON,\nD.C. 20549**\n\n \n\n**FORM\n8-K**\n\n \n\n**CURRENT\nREPORT**\n\nPURSUANT\nTO SECTION 13 OR 15(d) OF THE\n\nSECURITIES\nEXCHANGE ACT OF 1934\n\n \n\nDate\nof Report (Date of earliest event reported): May 31, 2026\n\n \n\n**BRIACELL\nTHERAPEUTICS CORP.**\n\n(Exact\nname of registrant as specified in its charter)\n\n \n\n**British\nColumbia A1**\n \n**47-1099599**\n\n(State\nor other jurisdiction\n\nof\nincorporation or organization)\n\n \n\n(I.R.S.\nEmployer\n\nIdentification\nNo.)\n\n \n \n \n\n**Suite\n300 - 235 15th Street**\n\n**West\nVancouver, BC V7T 2X1**\n\n \n**V7T\n2X1**\n\n(Address\nof principal executive offices)\n \n(Zip\nCode)\n\n \n\n(604)\n921-1810\n\n(Registrant’s\ntelephone number, including area code)\n\n \n\nCommission\nFile No. 001-40101\n\n \n\nCheck\nthe appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under\nany of the following provisions (see General Instruction A.2. below):\n\n \n\n☐\nWritten\ncommunications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n \n\n☐\nSoliciting\nmaterial pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n \n\n☐\nPre-commencement\ncommunications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n \n\n☐\nPre-commencement\ncommunications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities\nregistered under Section 12(b) of the Act:\n\n \n\n**Title\nof each class**\n \n**Trading\nSymbol(s)**\n \n**Name\nof each exchange on which registered**\n\nCommon\nShares, no par value\n \nBCTX\n \nThe\nNasdaq Stock Market LLC\n\nWarrants\nto purchase common shares, no par value\n \nBCTXL\nand BCTXZ\n \nThe\nNasdaq Stock Market LLC\n\n \n\nIndicate\nby check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)\nor Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).\n\n \n\nEmerging\ngrowth company ☒\n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐"}